Temedica expands its Advisory Board with former Gematik CEO Markus Leyck
Dieken

EQS-News: Temedica GmbH / Key word(s): Personnel
Temedica expands its Advisory Board with former Gematik CEO Markus Leyck
Dieken

16.05.2024 / 13:11 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Temedica expands its Advisory Board with former Gematik CEO Markus Leyck
Dieken

  * Dr. med. Markus Leyck Dieken, former CEO of Gematik, joins the Advisory
    Board of Temedica.

  * Dr. Leyck Dieken is recognized as an innovator and leading figure in the
    digital transformation of healthcare and brings profound experience from
    the life sciences industry.

Munich, May 16, 2024 - The Munich-based health insights company Temedica
announces the addition of Dr. med. Markus Leyck Dieken as a new member of
its Advisory Board. The former Gematik CEO will particularly advise Temedica
on strategic-regulatory issues. He is a seasoned expert with many years of
clinical experience as a specialist in internal and emergency medicine,
combined with 25 years in the biotech industry, where he worked in the
development, production, and marketing of biotechnological products,
including vaccines and biosimilars.


Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=f8c08af6a566568b8d174773f53281ea
Image title: L to R Markus Leyck Dieken, Gloria Seibert (CEO and founder of
Temedica), Benjamin Friedrich (Chief Medical Officer und co-founder of
Temedica)

L to R Markus Leyck Dieken, Gloria Seibert (CEO and founder of Temedica),
Benjamin Friedrich (Chief Medical Officer und co-founder of Temedica)

Gloria Seibert, CEO of Temedica, comments on this significant step:

"Adding Dr. Markus Leyck Dieken to our Advisory Board is an immense gain for
Temedica. His expertise in market access and reimbursement, as well as his
role in political and health policy committees, make him a valued member and
will help us further enhance our leading position in the area of real-world
evidence and the personalization of medicine."

Leyck Dieken played a central role in the development and market leadership
of diabetes therapies at Novo Nordisk, headed the EU vaccine business at
Novartis, and founded the first EU subsidiary of the California biotech
company InterMune. At Teva Pharmaceuticals, he expanded the range of
original preparations and made a significant contribution to combating
antibiotic resistance at Shionogi Europe. As CEO of Gematik, Leyck Dieken
was significantly involved in the digital transformation of the German
healthcare system, particularly through the introduction of electronic
health records and digital prescriptions.

Dr. med. Markus Leyck Dieken emphasizes:

"The innovative approach and entrepreneurial drive of Temedica have deeply
impressed me. With today's digital capabilities, we can use information in
unprecedented ways for research and improving patient care. Therefore, I am
pleased to contribute to Temedica and utilize the enormous potential of
real-world evidence for the entire industry."

Leyck Dieken is recognized as a long-standing, well-connected partner of
many stakeholders and brings valuable international perspectives and a deep
understanding of regulatory issues to Temedica.

About Temedica

Temedica is a health insights company based in Munich. Since 2016, it
operates Europe's leading ecosystem for real-world insights in the
healthcare sector. Temedica's mission is to enable personalized and
individualized medicine, thereby focusing on patients and their individual
needs. The company achieves this by linking health-related data from various
sources, which are processed into valuable insights in compliance with the
GDPR.

Temedica is backed by a consortium of renowned investors with many years of
experience in the biopharmaceutical industry, including the founding
investors of BioNTech. For further information, please visit
https://temedica.com/en/.

For further information and media inquiries, please contact:

Temedica GmbH

Anna Hauner

Corporate Communications

T: + 49 175 431 030 1

Email: pr@temedica.com


---------------------------------------------------------------------------

16.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

1904201 16.05.2024 CET/CEST